Launch Date: 24-06-2020

Aprazer Healthcare Launched Rifaxigem ( Rifaximin) which is a medication indicated for the treatment of IBS with Diarrhea and Hepatic Encephalopathy.

Launch Date: 03-06-2020

Aprazer Healthcare Launched DASAKAST (Dasatinib ) which is a medication used to treat newly diagnosed adults Philadelphia Chromosome -Positive( Ph+ ) Chronic Myeloid Leukemia in Chronic Phase, Advanced Chronic Leukemia & Acute Lymphoblastic Leukemia.

Aprazer Healthcare Launched ABIRAKAST (Abiraterone acetate ) which is a medication used to treat prostate cancer specifically it is used together with corticosteroid for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC)

Aprazer Healthcare Launched SORAFEKAST (Sorafenib Tablets ) is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.

Launch Date: 21-12-2019

Aprazer Healthcare Launched IMATIKAST (IMATINIB ) which is a medication used to treat
• Myelodysplastic/Myeloproliferative Diseases.
• Hypereosinophilic Syndrome and/or Chronic Eosinophilic Leukemia.
• Chronic Myeloid Leukemia Philadelphia-Chromosome-positive.
• Dermatofibrosarcoma Protuberans.
• Mastocytosis.
• Gastrointestinal Stromal Tumors.

Launch Date: 06-12-2019

Aprazer Healthcare Launched HEPAKAST containing l-leucine; l – isoleucine: l-valine. HEPAKAST is a Health Supplement indicated in Hepatic Encephalopathy & other Liver Diseases.

Aprazer Healthcare Launched under its brand Sofokast Plus, the generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg Tablet, for the treatment of patients with chronic hepatitis C virus (HCV) infection.

Aprazer now has ambitious plans to specialize in Oncological Tablet/Capsules dosage forms , as the next giant step. Towards the initial step, Aprazer has Tied up with BDR International for products Abiraterone & Sorafenib .

BDR has state – of – the – art manufacturing unit, specialized in Oncology oral formulations, is already commissioned and is into production. This unit located in Vadodara, Gujarat State is both WHO GMP and EU-GMP compliant.

BDR has a new unit under manufacturing site in Halol District in Gujarat has been acquired and construction work is all set to commence. Once ready and operational, this facility will target for approval from various international accreditation agencies, including from US, Europe, African and Asian Health Authorities.

Aprazer Healthcare Launched TAFSURE (Tenofovir alafenamide ) is a nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir. It was developed by Gilead Sciences based on the protide technology of Chris McGuigan for use in the treatment of HIV/AIDS and chronic hepatitis B, and is applied in the form of tenofovir alafenamide fumarate

Akums Drugs & Pharmaceuticals Limited – Akums is India’s single largest Contract Research and Manufacturing (CRAMS) organization responsible for manufacturing approximately 11-12 % of all drugs consumed in the country. The organization offers a comprehensive range of services starting from formulation development to market launch all en suite. Akums 9 state of the art facilities are equipped to produce all modern dosage forms — tablets, hard gelatin capsules, soft gelatin capsules, powder in sachets, liquid syrups and suspensions, injections, eye/ear drops, ointments, creams, gels, lotions, ayurveda and herbal preparations, nutraceutical and cosmetic preparations and many more. Akums offers significant manufacturing capacities